Therapeutic Asset Ratings
414 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
azd8853
Colorectal Cancer
AstraZeneca
P1/2
CC
(40)
BOLD-100
Colorectal Cancer
Bold Therapeutics, Inc.
P1/2
CC
(40)
Camizestrant
Colorectal Cancer
AstraZeneca
P1/2
CC
(40)
Carbon Nanoparticle-Loaded Iron
Colorectal Cancer
Sichuan Enray Pharmaceutical Sciences Company
P1/2
CC
(40)
Chm-2101 Car-T Cells
Colorectal Cancer
Chimeric Therapeutics
P1/2
CC
(40)
ct3001
Colorectal Cancer
Crossignal Therapeutics, Inc.
P1/2
CC
(40)
Darovasertib
Colorectal Cancer
IDEAYA Biosciences
P1/2
CC
(40)
D-isoascorbic acid
Colorectal Cancer
Nazarbayev University
P1/2
CC
(40)
Eb-Duo-Car-Nk-Cea/Gcc
Colorectal Cancer
Beijing Biotech
P1/2
CC
(40)
EBNK-001
Colorectal Cancer
Essen Biotech
P1/2
CC
(40)
Etx-19477
Colorectal Cancer
858 Therapeutics, Inc.
P1/2
CC
(40)
Fmc-376
Colorectal Cancer
Frontier Medicines Corporation
P1/2
CC
(40)
Fog-001
Colorectal Cancer
Parabilis Medicines, Inc.
P1/2
CC
(40)
gm103
Colorectal Cancer
GeneMedicine Co., Ltd.
P1/2
CC
(40)
il-15
Colorectal Cancer
Essen Biotech
P1/2
CC
(40)
immunoglobulin G1-kappa, anti-[Homo sapiens KLRB1 (killer cell lectin like receptor B1, NKR-P1A, natural killer cell surface protein P1A, CLEC5B, CD161)], Homo sapiens monoclonal antibody; gamma1 heavy chain Homo sapiens (1-450) [VH (Homo sapiens IGHV3-23*01 (96.9%) -(IGHD) -IGHJ4*01 (85.7%), Q120>R (113), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, G1v29 CH2 A84.4 (CH1 K120 (218) (122-219), hinge 1-15 (220-234), CH2 G1v29 CH2 N84.4>A (301) (235-344), CH3 D12 (360), L14 (362) (345-449), CHS K2>del (450)) (122-450)], (224-214')-disulfide with kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (94.7%) -IGKJ4*01 (91.7%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (153'), V101 (191') (108'-214')]; dimer (230-230'':233-233'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1 lacking the glutamine synthetase (GS-KO) gene, non-glycosylated
Colorectal Cancer
Immunitas Therapeutics
P1/2
CC
(40)
Immunoglobulin G1-kappa, anti-[Homo sapiens MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)] and anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], Homo sapiens monoclonal antibody, bispecific
Colorectal Cancer
Betta Pharmaceuticals Co., Ltd.
P1/2
CC
(40)
ipn01194
Colorectal Cancer
Ipsen
P1/2
CC
(40)
jk08
Colorectal Cancer
Salubris Biotherapeutics Inc
P1/2
CC
(40)
Kras Neoantigen Nanovaccine
Colorectal Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
P1/2
CC
(40)
Lorazepam
Colorectal Cancer
Merck Sharp & Dohme LLC
P1/2
CC
(40)
lyl273
Colorectal Cancer
Lyell Immunopharma, Inc.
P1/2
CC
(40)
Mcla-158
Colorectal Cancer
Merus B.V.
P1/2
CC
(40)
N-Acetyl-L-Cysteine
Colorectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
P1/2
CC
(40)
neo212
Colorectal Cancer
Neonc Technologies, Inc.
P1/2
CC
(40)
Showing 201 to 225 of 414 assets
Previous
Page 9 of 17
Next
